Schizophrenia News and Research

Latest Schizophrenia News and Research

EC approves Janssen’s DACOGEN for treatment of de novo acute myeloid leukaemia

Janssen-Cilag International NV announced today that the European Commission has approved the marketing authorisation for DACOGEN(decitabine) for the treatment of adult patients (age 65 years and above) with newly diagnosed de novo or secondary acute myeloid leukaemia (AML), according to the World Health Organisation (WHO) classification, who are not candidates for standard induction chemotherapy.

28 Sep 2012

BioLineRx’s BL-1020 safe and effective in treating schizophrenia

BioLineRx, a biopharmaceutical development company, announced today the publication of results from the Phase II EAGLE clinical trial for BL-1020, a first in class, orally available, GABA-enhanced antipsychotic for the treatment of schizophrenia, showing that BL-1020 is safe and effective in improving schizophrenia, in addition to improving cognitive impairment associated with this condition.

28 Sep 2012

FIT in shape for new role in ulcerative colitis monitoring

Fecal immunochemical tests could allow noninvasive assessment of patients with ulcerative colitis, say the authors of a Japanese study.

27 Sep 2012

Poor emotion recognition in patients at risk for schizophrenia

Individuals at risk for schizophrenia show significant deficits in facial affect recognition compared with mentally healthy individuals, researchers report.

27 Sep 2012

Short-course amphotericin is cost-effective for cryptococcal meningitis

The treatment of cryptococcal meningitis in resource-limited settings is most effective with a short 1-week course of amphotericin induction therapy coupled with high-dose fluconazole for at least 2 weeks, a Ugandan study suggests.

26 Sep 2012

First-episode schizophrenia patients show widespread cognitive deficits

Antipsychotic-naïve patients with a first-episode of schizophrenia show deficits in all cognitive domains compared with mentally healthy individuals, researchers report.

26 Sep 2012

Study reveals key difference in brain development between human and chimpanzee

Research comparing brain development in humans and our closest nonhuman primate relatives, chimpanzees, reveals how quickly myelin in the cerebral cortex grows, shedding light on the evolution of human cognitive development and the vulnerability of humans to psychiatric disorders, a GW professor finds.

26 Sep 2012

Maternal obstetric problems linked to schizophrenia risk

Certain maternal pregnancy complications are associated with an increased risk for schizophrenia spectrum psychoses among individuals at high genetic risk for the condition, Finnish research shows.

25 Sep 2012

Suicide attempts common in bipolar disorder inpatients

Results from a Norwegian study show that the prevalence of attempted suicide is high among inpatients with bipolar disorder, with nearly half of patients having attempted to take their own lives at least once.

25 Sep 2012

InterCure signs strategic service agreement with private company

XTL Biopharmaceuticals Ltd. today announced that InterCure Ltd., which is approximately 45.4% (50.79% on a fully diluted basis) held by XTL, signed a strategic service agreement with a private company wholly owned by Mr. Shay Ben Yitzhak and Mr. Avner Yassur.

25 Sep 2012

Age at onset influences juvenile dermatomyositis course

Children diagnosed with juvenile dermatomyositis at age 3 years or earlier have milder symptoms than patients with later onset, research suggests.

24 Sep 2012

BG-12 effective for relapsing–remitting multiple sclerosis

Results of the CONFIRM and DEFINE studies suggest that dimethyl fumarate should be considered as an oral treatment for patients with relapsing–remitting multiple sclerosis.

24 Sep 2012

BioLineRx receives U.S. patent allowance for BL-1020 to treat schizophrenia

BioLineRx, a biopharmaceutical development company, announced today that a Notice of Allowance has been received from the United States Patent and Trademark Office (USPTO) claiming the crystalline form of BL-1020, a first-in-class orally available treatment for schizophrenia.

24 Sep 2012

Researchers solve mystery of radial glial cells

Researchers at Cold Spring Harbor Laboratory (CSHL) have solved an important piece of one of neuroscience's outstanding puzzles: how progenitor cells in the developing mammalian brain reproduce themselves while also giving birth to neurons that will populate the emerging cerebral cortex, the seat of cognition and executive function in the mature brain.

24 Sep 2012

Prevalence of sexual violence against mental health patients ‘alarming’

Around a fifth of patients with mental illnesses report being the victims of sexual violence, results from a Brazilian study show.

21 Sep 2012

First extensive analysis of Allen Human Brain Atlas

Scientists at the Allen Institute for Brain Science reported in the latest issue of the journal Nature that human brains share a consistent genetic blueprint and possess enormous biochemical complexity. The findings stem from the first deep and large-scale analysis of the vast data set publicly available in the Allen Human Brain Atlas.

21 Sep 2012